tbuckley/cabot-search huggingface dataset:
AB0469 Evolution of Anthropometric Profile and Habit Food after 10 Years in Systemic Lupus Erythematosus Patients:
Authors: L.S. Souza, J. Calzza, Έ. Cassol, R.M. Xavier, O. Monticielo
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is an autoimmune inflammatory disease that affects various organs and systems. Cardiovascular disease is a common complication and is associated with factors inherent to the SLE and environmental factors such as overweight and poor eating habits. In addition, obesity has been speculated as a contributing factor to the onset and progression of autoimmune diseases. <h3>Objectives</h3> Evaluate the anthropometric profile and food habit after 10 years of follow-up of a group of patients with SLE and identify possible association with chronicity index and disease activity. <h3>Methods</h3> We evaluated 55 patients with SLE in two moments with an interval of 10 years, coming from a care referral center for SLE in Hospital de Clínicas de Porto Alegre, Brazil. For chronicity and activity was used Systemic Lupus International Collaborating Clinics (SLICC) index and Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), respectively. Body Mass Index (BMI), Body Fat Percentage (BFP) and waist circumference (WC) were the anthropometric data collected in accordance with the standards of the World Health Organization (WHO). The total cholesterol, LDL, HDL and triglycerides were performed as routine care. The study was approved by the Ethics Committee of the Universidade Federal of Rio Grande do Sul (UFRGS) and all patients who agreed to participate in the study met the consent and informed. <h3>Results</h3> <h3>Conclusions</h3> Our study revealed a worsening in the lipid profile and a higher concentration of abdominal fat in patients with SLE after 10 years of follow-up, although diet has remained stable. Factors related to disease or treatment may have influenced these results, but were not assessed in this study. These findings serve as a warning to us take better care of the nutritional status and lipid profile of our patients. <h3>References</h3> The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: A systematic review. S.R. Schoenfeld et al./Seminars in Arthritis and Rheumatism 43 (2013) 77–95. Obesity in autoimmune diseases: Not a passive bystander. M. Versini et al./Autoimmunity Reviews 13 (2014) 981–1000. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort Bruce IN, et al. Ann Rheum Dis 2014;0:1–8. doi:10.1136/annrheumdis-2013-205171 World Health Organization. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. Geneva: World Health Organization;1995 (WHO Technical Report Series, no. 854). <h3>Disclosure of Interest</h3> None declared
PTU-093 An Exploration of Adverse Reactions to Foods in Adults with Crohn’s Disease
Authors: A Morris, B Leach
Journal: Gut (2016)

<h3>Introduction</h3> Crohn’s Disease (CD) has been associated with an increased risk of food allergies due to damage to the epithelial intercellular junctions and the ensuing immune response. However, since this population has increased micronutrient requirements it is important that dietetic advice is sought in favour of self-imposed dietary restrictions. The aim of this study was to explore individuals with CD’s experiences of self-reported adverse reactions to food. <h3>Methods</h3> A phenomenological design utilised in-depth semi-structured interviews with adults with CD. Convenience sample recruitment via Coventry Ileostomy and Internal Pouch Support Group was employed. A topic guide included the areas of experinces of adverse reactions to foods, ways of coping and impact of adverse reactions to foods. Interviews were recorded and transcribed verbatim. Data was explored and findings interpreted using Interpretive Phenomenological Analysis. NVIVO software was used for data management. Member checking and internal peer review were undertaken. Participants gave written informed consent. <h3>Results</h3> Ten adults (4 men 6 women) with a mean age of 52.2 (±19) years had a mean experience of 20.2 years living with CD. Four main themes emerged which illustrated the experience of adverse reactions to food (1) Physiological symptoms; pain; swelling; diarrhoea; breathing difficulty (2) Difficulties Identifying and telling the difference between allergy and intolerance; being able to identify an allergic reaction, Hypersensitivity to food items dependent on situation rose, e.g. inside/outside home (3) Psychological reaction to food, questioning their own working diagnosis and reactions to certain foods (4) Dietary self-management; excluding offending foods from diet; taking antihistamine medication; not re-engaging with dietitians due to perceived lack of adverse food reaction knowledge in CD. <h3>Conclusion</h3> Adults with CD reported common adverse reactions to certain foods. Coping strategies included identifying the symptoms and ascribing them either to an allergic reaction or intolerance, with subsequent exclusion of offending foods or decisions on excluding foods likely to cause intolerance. Health professionals may need to be aware and more supportive around reports of adverse reactions to foods and the potential impact on quality of life in CD. Building working relationships is required to support the patient and ensure the nutritional consequences of food avoidance are minimised. <h3>Disclosure of Interest</h3> None Declared
Chronic GVHD Leads to Shortening of Telomeres in Subsets of Lymphoid Cells but Not in Granulocytes in Long-Term Survivors after Allogeneic HSCT.
Authors: Gabriela M. Baerlocher, Alicia Rovo, Sybille Matthey, Astrid Mueller, Thomas Daikeler, Michael Medinger, Jörg Halter, Dominik Heim, Alois Gratwohl, Andre Tichelli
Journal: Blood (2006)
CBIO-43ROLE OF BASIGIN-3 IN MMP EXPRESSION IN GBM
Authors: Samantha M. Wightman, Robert J. Belton, Johnathan E. Lawrence, Robert J. Winn
Journal: Neuro-Oncology (2015)

Glioblastoma multiforme (GBM) is one of the most aggressive forms of brain tumor. With the current standard of care, the five year survival rate for GBM patients is less than 3%. An understanding of the molecular mechanisms promoting growth and survival of GBMs may result in novel treatments for this disease. A recent report indicated that the expression of the protein Basigin is a significant prognostic indicator for tumor grade in GBM patients, with tumors expressing highest levels of basigin protein correlating with the most aggressive tumors (Yang 2013). The Basigin gene family contains four isoforms, with Basigin-2 the predominant isoform expressed in both normal and diseased tissue. In 2011, Liao et al, suggested that Basigin-3 interacts with Basigin-2 in Human Hepatocellular Carcinoma (HHC), leading to decreased tumor growth and invasion. Because the Basigin-2 protein (CD-147/EMMPRIN) is a known inducer of matrix metalloproteinase (MMP) the inhibition of Basigin-2 through its interaction with Basigin-3 should decrease both tumor growth and MMP expression. To test this hypothesis, a recombinant Basigin-3/mKate2 fluorescent protein fusion was overexpressed in a GBM cell line (LN229), and RT-qPCR was used to measure MMP gene expression. Confocal microscopy and western blot analysis confirmed the over-expression of Basigin-3 in the transfected populations. However, the overexpression of Basigin-3 did not reduce the expression of MMP-1, MMP-2, and MMP-3. Our data suggest that the role of Basigin-3 in GBM may be different from what was shown in HHCs. Currently, we are performing FRET analysis between Basigin-2 and Basigin-3 to confirm their interaction in our model.
AB0883 Cryopyrinopathy Detected in 10 Family Members of 4 Generations: Importance of Interdisciplinary Collaboration:
Authors: S. Fingerhutova, J. Franova, L. Prochazkova, P. Dolezalova
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Cryopyrin-associated periodic syndromes (CAPS)are autoinflammatory disorders with autosomal dominant inheritance. Although Muckle-Wells Syndrome (MWS) stands in the middle of theCAPS severity spectrum, it is associated with the high risk of severe late complications that include hearing loss, vision impairment and AA amyloidosis affecting about 26% of individuals. Early diagnosis and appropriate treatment with interleukin-1 (IL-1)blockade may prevent their development <h3>Objectives</h3> Analysis of a single paediatric patient trajectory leading to the revelation of multiple members of his family suffering with MWS, description of evolving disease phenotype in patients from different generations. To stress an importance of disease awareness as well as interdisciplinary collaboration in detecting familiar conditions affecting both children and adults. <h3>Methods</h3> Multiple-case study. <h3>Results</h3> A 3-years old Caucasian boy was referred to the allergologyclinic by his primary care paediatrician for recurrent flares of non-pruritic urticarial rash from about 4 months of age. There were no other symptoms of note. Detailed family history suggested presence of rash in other family members.Working together, paediatric and adult rheumatologist detected additional 9 individuals suffering with variable combinations of fever episodes with rash (all), episodic arthritis, eye inflammation, hearing loss, headache and proteinuria (Graph 1, Table 1). Patient9s great grandmother died in 52 years of age from renal failure. Although renal biopsy was not performed at the time, presence of other symptoms as reported by her children made clinical diagnosis of MWS and amyloidosis very likely. Genetic analysis of exon 3 of NLRP3 gene in affected individuals revealed heterozygous mutation c.1322C&gt;T causing change of amino acids p.Ala441Val and prompted referral to the autoinflammatory disease centre for biologic therapy. <h3>Conclusions</h3> In this family medical care was not primarily seeked by adults who have got used to their long-term and relatively mild symptoms. The diagnostic procedure was initiated by the paediatric referral. Detailed analysis of the symptoms suggests presence of the high risk of severe complications. Hearing loss and/or proteinuria have only been noticed in individuals older than 50 years of age. Importantly, younger members below 30 years have not yet developed any of these symptoms which may now be prevented with long-term biologict herapy. This multi-case report illustrates importance of the high degree of suspicion as well as close collaboration between paediatric and adult specialists in order to establish timely diagnosis and initiate appropriate investigations and treatment. <h3>Disclosure of Interest</h3> None declared
The HIV Protease Inhibitor Nelfinavir: A Unique Oral Drug That Inhibits the Proteasome and AKT-Phosphorylation, Induces ER Stress and Sensitizes Bortezomib-Refractory Primary Myeloma Cells and Primary AML Cells towards Bortezomib
Authors: Christoph Driessen, Jürgen Bader, Marianne Kraus
Journal: Blood (2010)
FRI0260 Quantitative CT Indexes in ILD-SSC Patients with Different Autoantibodies: Table 1
Authors: A. Ariani, E. Bravi, M. Saracco, S. Parisi, F. De Gennaro, L. Idolazzi, M. Silva, V. Seletti, F. Lumetti, P. Caramaschi, C. Benini, F.C. Bodini, C.A. Scirè, G. Lucchini, D. Santilli, D. Imberti, E. Arrigoni, E. Michieletti, R. Pellerito, E. Fusaro, N. Sverzellati
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Quantitative Computed Tomography (QCT) is an innovative method to assess the severity of interstitial lung disease (ILD) related to systemic sclerosis (SSc). QCT is correlated to semi-quantitative radiological scores (SQs) and functional outcomes (e.g. FVC, DLco, oxygen desaturation after exercise) in SSc patients. However, the autoimmune profile can deeply influence the respiratory system9s involvement. <h3>Objectives</h3> The main aim of this study is to verify the correlation between SQs, FVC, DLco and QCT in SSc patients clustered according to their autoimmunity. <h3>Methods</h3> Three hundred three (303) SSc patients were enrolled and underwent functional and radiological assessment. Chest CTs of each patient were evaluated with both SQs and Horos (a software up to perform voxel-wise analysis) in order to obtain QCT indexes. <h3>Results</h3> Patients were divided in three groups (94 with ACA, 93 with antiScl70, 116 with other autoantibodies). QCT indexes taken into account were kurtosis (Kurt), skewness (Skew), Standard Deviation (SDev), Mean Lung Attenuation (MLA) and fibrosis ratio (FR). Except for the last one, all QCT indexes were assessed both in the parenchymal (pQCT) and in the whole lung (tQCT). The statistically significant (p&lt;0,05) correlation coefficients between SQs, FVC and DLco vs QCT are listed in Table 1. In ACA patients there are not correlations between DLco and QCT indexes. <h3>Conclusions</h3> Our results confirm that the majority of QCT indexes are correlated to SQS and functional outcomes. The strongest correlation coefficients were in the antiScl70 subgroup while the weakest ones were in ACA patients. This relevant difference, possibly due to the different prevalence of ILD and type of lung involvement in these two subgroups, should be taken into account when applying the QCT assessment to SSc patients. <h3>Disclosure of Interest</h3> None declared
FRI0628-HPR Advanced Practice Musculoskeletal Physiotherapists in Rheumatology- A National Report of The 2014 Data
Authors: J. Ashton, R. Breen, A. Brennan, E. Callanan, C. Farrell, D. Moore, P. Kenny, D. Carey, O. Fitzgerald
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Research studies have supported the role of Advanced Practice Physiotherapists (APP9s) acting as first contact practitioners in the management of musculoskeletal (MSK) patients<sup>1</sup>. In 2012, funding was approved for 24 APP posts in Ireland through the Clinical Strategy and Care Programmes Directorate of the Health Service Executive (HSE) in Ireland. These posts were to provide orthopaedic and rheumatology triage clinics across 16 hospitals throughout the country as a waiting list initative for patients with MSK complaints. <h3>Objectives</h3> i)To present the data reported on the throughput of Rheumatology patients seen by the APPs nationally in 2014. <h3>Methods</h3> 13 sites provided MSK triage through rheumatology clinics nationally in 2014. While each post has a target of seeing 1,000 patients per year it has been reported that APP9s see a ratio of 5:1 orthopaedic to rheumatology patients. Data was collected monthly from all sites and reported directly to the rheumatology clinical care programme. Descriptive data was analysed using a Microsoft® Excel package. <h3>Results</h3> 2,177 new and 530 return rheumatology patients were seen nationally in 2014. Regarding new patients the most common areas were shoulder (n=329, 15.1%) and lumbar spine (n=288, 13.2%), 35.2% (n=766) had multiple pain sites. Regarding waiting times 58.6% (n=1275) were seen within 6months of referral and 21% (n=457) had imaging ordered. 40.1% (n=873) were referred for physiotherapy within the hospital or primary care. 63.3% (n=1378) were discharged directly from the APP clinic and 15% (n=327) were referred on to another medical speciality. <h3>Conclusions</h3> APPs have been effective in triaging MSK referrals within a rheumatology setting. A large proportion of patients were discharged back to the referring source. <h3>References</h3> Desmeules et al (2012) Advanced practice physiotherapy in patients with musculoskeletal disorders: a systematic review. BMC Musculoskeletal Disorders. 13: 107–128. <h3>Acknowledgement</h3> The authors would like to acknowledge the work of the APP9s nationally in the collection of the data. <h3>Disclosure of Interest</h3> None declared
Telomere Length and Telomerase Assay Assist in Identifying Novel Telomere Gene Complex Mutations in a Cohort of Patients with Aplastic Anemia
Authors: Shreyans Gandhi, Jie Jiang, Nana Benson-Quarm, Hanna Renshaw, Syed A Mian, Austin G. Kulasekararaj, Ghulam J Mufti, Judith C. W. Marsh
Journal: Blood (2015)
Initial Liver Iron Predicts Cardiac Chelation Efficacy of Deferasirox (Exjade®) Monotherapy in Chronically Transfused β-Thalassemia (β-Thal) Patients: 18- and 24-Month Data.
Authors: John C. Wood, Alexis A. Thompson, Carole Paley, Tara Glynos, Barinder Kang, Patricia J. Giardina, Paul R. Harmatz, Thomas Coates
Journal: Blood (2009)
Update of Experience with Fludarabine, Cyclophosphamide, Mitoxantrone Plus Rituximab (FCM-R) in Frontline Therapy for Chronic Lymphocytic Leukemia (CLL).
Authors: Stefan Faderl, William Wierda, Alessandra Ferrajoli, Susan O’Brien, Farhad Ravandi, Hagop M. Kantarjian, Brandi L. Showalter, Susan Lerner, Michael J. Keating
Journal: Blood (2007)
Features and Risk Factors of Peripheral Neuropathy during Treatment of Advanced Multiple Myeloma with Bortezomib.
Authors: Jean El-Cheikh, Anne Marie Stoppa, Segolene Duran, Reda Bouabdallah, Norbert Vey, Diane Coso, Vadim Ivanov, Aude Charbonnier, Catherine Faucher, Jean Marc Schiano de Collela, Jacques Camerlo, Jean-Albert Gastaut, Didier Blaise, Mohamad Mohty
Journal: Blood (2006)
Elderly AML Patients Treated with Intensive Chemotherapy- Developing A Prognostic Scoring System. A Study On 381 Patients From British Columbia
Authors: Satish Krishnan, Huihua Li, Yasser R Abou Mourad, Michael J. Barnett, Raewyn Broady, Donna L. Forrest, Stephen H. Nantel, Sujaatha Narayanan, Thomas J. Nevill, Maryse M. Power, John D. Shepherd, Kevin W. Song, Heather J. Sutherland, Cynthia L. Toze, Donna E. Hogge
Journal: Blood (2011)
PTH-091 Incidental Diagnosis of Inflammatory Bowel Disease Through The Bowel Cancer Screening Programme: A 7 Year Experience
Authors: U Nosegbe, J Scott, R Butcher, A Abbasi, R Prudham, R George, JK Limdi
Journal: Gut (2016)

<h3>Introduction</h3> The UK Bowel Cancer Screening Programme (BCSP) launched in 2006, currently screens individuals aged 60–74 years through a Faecal Occult Blood test (FOBt). If positive patients are invited for colonoscopy. We reported in 2012 the first ever experience of incidental diagnosis of IBD through a screening cohort and now present a 7 year experience. <h3>Methods</h3> We conducted a retrospective assessment of BCSP outcomes at our centre between April 2008 (launch) and December 2015. Assessment included the number of patients invited for screening, number successfully screened (inclusive of “normal” and “abnormal” FOBt) and the number of index colonoscopies. In those with confirmed IBD diagnosis, clinical outcomes, symptoms at diagnosis, disease distribution and behaviour and treatments undertaken were recorded through patient record and case note reviews. <h3>Results</h3> Of 358,716 invited individuals 180,075 were adequately screened (uptake 50.2%) with FOBt positivity of 1.83%. Of 3598 index colonoscopies undertaken, an incidental diagnosis of IBD was made in 37 (12 female) patients. Ulcerative Colitis (UC) was diagnosed in in 22 (59.4%) patients and Crohn’s (CD) in 10 (27.0%). A further 5 (13.5%) patients were diagnosed with IBD-type unclassified (IBDU) of which 2 were reclassified as UC through follow up. In those diagnosed with UC initially 9 (41.0%) had proctitis, 8 (36.4%) left sided disease and 5 (22.7%) had extensive disease. The majority of CD patients (80%) had an isolated colonic distribution and behaviour was non-stricturing and non-penetrating (70%) or stricturing (30%). Follow up data was available for 25 (67.6%) patients over a median of 40.5 months (range 3–87) of which 14 patients were asymptomatic at diagnosis. Eleven (78.6%) became symptomatic and 2 (8.3%) demonstrated phenotypic progression during follow up. Treatment included 5 ASA (23), steroids (14), Immunomodulation (Azathioprine – 7: Methotrexate – 1) and Anti-TNF (Infliximab -2; Adalimumab – 1). Median time to immunomodulation was 29.0 months and to anti-TNF treatment was 28.0 months. Five patients died: 3 from unrelated causes, 1 from an unknown cause and 1 seven days after subtotal colectomy (undertaken 54 months after diagnosis with symptomatic IBDU). <h3>Conclusion</h3> An incidental diagnosis of IBD at screening is not uncommon, with an incidence of 1.0% in our cohort . A proportion of patients demonstrate significant disease progression requiring immunomodulation, biologic therapy or surgery. IBD detection from screening provides a unique model to study early disease in ‘elderly’ (and potentially asymptomatic) patients. <h3>Disclosure of Interest</h3> None Declared
Cyclosporine a and Mycophenolate Mofetil Vs Cyclosporine a and Methotrexate as Gvhd Prophylaxis in Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation from HLA-Identical Sibling Donor.
Authors: Jose Luis Piñana, David Valcarcel, Rodrigo Martino, Francesc Fernandez, Pere Barba, Montserrat Rovira, Enric Carreras, Anna Sureda, Jorge Sierra
Journal: Blood (2008)
Досвід використання пробіотичних штамів Lactobacillus acidophilus R0052 та Lactobacillus rhamnosus R0011 у дітей з опіковою травмою
Authors: M.V. Patsera, Ya.S. Skrypnykova, O.H. Ivan’ko
Journal: GASTROENTEROLOGY (2016)

На сьогодні опіки посідають друге місце серед усіх травм дітей. Основною причиною летальних наслідків у випадку виражених та глибоких опіків є інфекція, що виникає у 23–82 % усіх випадків опіків. Раціональна антибактеріальна терапія має велике значення в боротьбі з генералізованою інфекцією. Метою цього дослідження було ретельне вивчення епідеміології та характеристики антибіотик-асоційованої діареї (ААД) у хворих дітей з опіками, а також можливість запобігання цій діареї, що виникала внаслідок антибактеріальної терапії в пацієнтів Обласного опікового відділення м. Запоріжжя. Протягом 2012–2015 років ми спостерігали 438 дітей з опіковими травмами, які приймали антибіотики. У цих госпіталізованих дітей було знайдено специфічні для ААД Clostridium difficile токсини А + В у фекаліях. Це дозволило діагностувати Clostridium difficile-ентероколіт, пов’язаний з прийомом хворими антимікробних препаратів (A4.07, МКБ‑10). Розроблено профілактичні методи AAД, а саме призначення з перших годин перебування в стаціонарі per os пробіотичного засобу Lactobacillus acidophilus R0052 і Lactobacillus rhamnosus R0011 у складі препарату Lacidofil®. Використання пробіотичних штамів з антитоксичною активністю щодо Clostridium difficile скорочує в 3,4 раза число випадків антибіотик-асоційованої діареї в дітей з опіками та зменшує тяжкість її симптомів.